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ABSTRACT
Background Intravenous recombinant tissue plasminogen 
activator (r- tPA) and urokinase (UK) are both recommended for 
the treatment of acute ischaemic stroke (AIS) in China, but with 
few comparative outcome data being available. We aimed to 
compare the outcomes of these two thrombolytic agents for the 
treatment of patients within 4.5 hours of onset of AIS in routine 
clinical practice in China.
Methods A pre- planned, prospective, nationwide, 
multicentre, real- world registry of consecutive patients 
with AIS (age ≥18 years) who received r- tPA or UK 
within 4.5 hours of symptom onset according to local 
decision- making and guideline recommendations during 
2017–2019. The primary effectiveness outcome was 
the proportion of patients with an excellent functional 
outcome (defined by modified Rankin scale scores 0 to 
1) at 90 days. The key safety endpoint was symptomatic 
intracranial haemorrhage according to standard definitions. 
Multivariable logistic regression was used for comparative 
analysis, with adjustment according to propensity scores to 
ensure balance in baseline characteristics.
Results Overall, 4130 patients with AIS were registered but 
320 had incomplete or missing data, leaving 3810 with available 
data for analysis of whom 2666 received r- tPA (median dose 
0.88 (IQR 0.78–0.90) mg/kg) and 1144 received UK (1.71 (1.43–
2.00)×104 international unit per kilogram). There were several 
significant intergroup differences in patient characteristics: 
r- tPA patients were more educated, had less history of stroke, 
lower systolic blood pressure, greater neurological impairment 
and shorter treatment times from symptom onset than UK 
patients. However, in adjusted analysis, the frequency of 
excellent outcome (OR 1.18, 95% CI 1.00 to 1.40, p=0.052) and 
symptomatic intracranial haemorrhage (OR 0.70, 95% CI 0.33 to 
1.47, p=0.344) were similar between groups.
Conclusions UK may be as effective and carry a similar 
safety profile as r- tPA in treating mild to moderate AIS 
within guidelines in China.
Registration http://www. clinicaltrials. gov. unique 
identifier: NCT02854592.
INTRODUCTION
Intravenous recombinant tissue plasminogen 
activator (r- tPA) is the regulatory- approved, 
guideline- recommended standard throm-
bolytic treatment for patients with acute 
ischaemic stroke (AIS) worldwide. However, 
another intravenous thrombolytic agent, 
urokinase (UK), is also variably used for the 
treatment of AIS in Asian countries, and is 
including being regulatory approved for 
such use in China1 a positive result in a large 
national multicentre clinical trial.2 Chinese 
guidelines recommend UK for use within 
6 hours of onset of AIS (class II, level B) as an 
alternative to r- tPA with its shorter (4.5 hours) 
therapeutic time window (class I, level B).1 3 
Given that UK has a much cheaper and may 
have an apparent longer therapeutic time 
window than r- tPA, additional comparative 
data for these two agents could have broader 
relevance to clinical practice, particularly in 
low resource settings. We undertook a ‘real 
world’ national, INtravenous Thrombolysis 
REgistry for Chinese Ischaemic Stroke within 
4.5 hours of onset (INTRECIS) registry study 
to compare the outcomes between intrave-
nous r- tPA and UK within 4.5 hours of AIS.
METHODS
Study design
INTRECIS was a nationwide, multicentre, 
prospective registry of consecutive adult 
patients (age ≥18 years) with CT or MRI 
confirmed AIS who were previously well 
(modified Rankin scale (mRS) scores 0 or 1) 
and were eligible for treatment with either 
intravenous r- tPA or UK within 4.5 hours of a 
definite time of onset of symptoms. Patients 
were excluded if they had a history of intrac-
ranial haemorrhage (subarachnoid, intrac-
ranial and haemorrhagic transformation of 
cerebral infarction); head injury or acute 
stroke within 3 months; known intracranial 
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tumour, arteriovenous malformation or aneurysm; intrac-
ranial or spinal cord surgery within 3 months; gastrointes-
tinal or urinary tract haemorrhage within the previous 21 
days; low blood glucose level (<2.7 mmol/L or <50 mg/
dL); use of heparin or oral anticoagulation therapy 
within 48 hours; use of warfarin with an international 
normalised ratio >1.7 or prothrombin time >15 s; severe 
systemic disease with poor life expectancy (<3 months); 
major surgery within 1 month; uncontrolled hyperten-
sion (systolic pressure ≥180 mm Hg and/or diastolic pres-
sure ≥100 mm Hg); thrombocytopenia (platelet count 
<10×109/L); and involvement in a clinical trial within 
3 months. After the attending clinician provided infor-
mation on the evidence for the agents, their costs and 
rationale for the research study, all patients and/or their 
legally authorised surrogate decided on which throm-
bolytic agent to use, and provided informed consent for 
data collection and follow- up.
Procedures
Participating patients with AIS received different doses 
of r- tPA (0.6–0.9 mg/kg over 60 min) or UK (1.0–1.5×1 
000 000 U/kg), according to their age and neurological 
severity. For example, higher dose was generally chosen 
for younger patients with greater neurological severity on 
the National Institutes of Health Stroke Scale (NIHSS), 
whereas lower doses were used for older patients with 
lower NIHSS scores. All other management, including 
the use of antiplatelets, statins and antihypertensive 
agents, were given according to guideline recommen-
dations. Demographic, clinical (including neurological 
severity on the NIHSS) and functional assessment on the 
mRS were obtained at admission, 24 hours, and 7 and 14 
days in- person, and at 90 days in- person or by telephone, 
post- thrombolysis.
Outcomes
The primary outcome was ‘excellent recovery’ (mRS scores 
0 to 1) at 90 days. Secondary outcomes were ‘functional 
independence’ (mRS scores 0 to 2), recurrent stroke, 
all- cause mortality and early change in NIHSS scores. 
The primary safety endpoint was symptomatic intracere-
bral haemorrhage (sICH), defined as an increase of ≥4 
on scores on the NIHSS caused by intracranial haemor-
rhage within 36 hours,4 with all clinician- reported details 
centrally adjudicated. All the patients with neurological 
worsening received CT or MRI to identify the occurrence 
of intracerebral haemorrhage. Other safety outcomes 
included any bleeding or severe adverse event.
Statistical analysis
Previous studies indicate that approximately 48% of 
patients with AIS have a 90- day favourable outcome (mRS 
0 to 1) after r- tPA,5 but such data are more limited for 
UK. We estimated that 2800 patients would be required 
for 90% power (two tailed α 0.05) to detect a 6% absolute 
intergroup difference in the primary outcome (ie, 48% vs 
42% in the r- tPA and UK groups, respectively). However, 
taking account of the greater utilisation of r- tPA over UK, 
and assuming 10% missing outcome data, the sample size 
was increased to 4000 patients, that of 2600 and 1400 for 
the r- tPA and UK groups, respectively.
We performed propensity score matching (PSM) 
between patients with guideline- recommended standard- 
dosage r- tPA (0.9 mg/kg) and UK (1.0–1.5×1 000 000 U). 
PSM was performed with the ratio of 1:1, calliper of 0.1 
and a nearest- neighbour matching strategy by R software 
V.3.6.3. PSM was operated with control factors including 
age, gender, body mass index, current smoker, current 
drinker, hypertension, diabetes mellitus, history of 
stroke, coronary heart disease, atrial fibrillation, onset- to- 
treatment time, door- to- needle time, systolic blood pres-
sure, NIHSS score at admission, pathological subtype of 
AIS according to the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) classification system, hospital classi-
fication and educational level.
Two- sample t- test or Wilcoxon rank test and χ2 test were 
used to assess differences in baseline variables according 
to continuous or categorical distribution, respectively. 
Propensity score analysis was used to adjust for baseline 
imbalances, whereby the score (predicted probability 
of a patient receiving r- tPA) calculated in a multivari-
able logistic regression model was used as a covariate in 
adjusted analyses. Differences between the two agents were 
assessed across six subgroups defined by age (<65 and ≥65 
years), sex, history of stroke and baseline NIHSS score 
(≤5 vs >5), onset to treatment time (<180 vs 180–270 min) 
and systolic blood pressure (<140 vs ≥140 mm Hg). Data 
are reported with ORs and 95% CIs.
Generalised estimating equation (GEE) models with 
normal distribution and identity link function were 
used for analysis of continuous outcomes with repeated 
measurements, such as change in NIHSS scores between 
admission and day 1 and day 14. The GEE model 
included treatment, time, and interaction between 
treatment and time as fixed effects, baseline measure-
ment and propensity score as covariates, and patient as 
a cluster effect. Sensitivity analyses of outcomes were 
performed by replacing propensity score with individual 
baseline covariates in regression models. All analyses were 
performed on a complete case series. Sensitivity analyses 
were performed by imputing missing baseline covariates 
using a simple imputation method based on their sample 
distributions (eg, imputation of a missing value for a 
continuous variable by a normal distribution derivation 
given sample mean and standard derivation). A p value 
<0.05 was considered statistically significant. All analyses 
were performed using SAS V.9.4 (SAS Institute, Cary, NC, 
USA).
RESULTS
Overall, 4130 consecutive patients with AIS were enrolled 
in the study between 1 April 2017 and 1 July 2019, of 
whom 245 were excluded for various reasons and 75 lost 
to follow- up (online supplemental figure S1). Thus, 3810 
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patients (2666 and 1144 in r- tPA and UK groups, respec-
tively) were included in the analysis set. Table 1 shows 
the baseline characteristics of participants, with the r- tPA 
group being more educated, had less history of stroke, 
lower systolic blood pressure, but presented with greater 
neurological deficit and shorter times from symptom 
onset to treatment, than those in the UK group. The 
distribution of r- tPA and UK across participating sites is 
shown in online supplemental figure S2.
Tables 2 and 3 show that the primary endpoint of excel-
lent recovery (mRS scores 0 to 1) at 90 days was similar 
between the two groups: r- tPA (71.3%) and UK (69.5%), 
with unadjusted OR 1.09 (95% CI 0.94 to 1.27, p=0.250) 
and adjusted OR 1.15 (95% CI 0.98 to 1.35, p=0.078). 
The distribution of the full range of mRS scores was 
comparable between the groups (figure 1). Table 2 also 
showed similarly comparable secondary clinical outcomes 
and safety between the two groups. The consistency of 
the results was confirmed in sensitivity analysis using 
different methods of adjustment for potential baseline 
confounders (table 3). Other than a borderline signifi-
cant effect of age and educational level on the primary 
outcome, there was consistency in primary effectiveness 
outcome across subgroups (online supplemental figure 
S3).
In addition, we determined the effectiveness and safety 
outcomes in PSM patients with guideline- recommended 
standard- dosage r- tPA (0.9 mg/kg) and UK (1.0–1.5×1 
Table 1 Baseline characteristics
Variable r- tPA (N=2666) UK (N=1144) P value
Dose, mg/U per kg 0.88 (0.78–0.90) 1.71 (1.43–2.00)×104 –
Age, years 63.8 (11.5) 63.5 (63.8) 0.399
Male 1827 (68.5) 779 (68.1) 0.791
BMI, kg/m2 24.1 (3.8) 24.2 (3.4) 0.490
Educational level 0.006
  Primary school degree or below 762 (28.6) 370 (32.3)
  Middle school degree 1623 (60.9) 685 (59.5)
  Bachelor degree or above 281 (10.5) 89 (7.8)
Current smoker 1006 (37.7) 442 (38.6) 0.599
Current drinker 607 (22.8) 279 (24.4) 0.278
Hypertension 1435/2599 (55.2) 599/1097 (54.6) 0.733
Coronary heart disease 394/2549 (15.5) 167/1069 (15.6) 0.900
History of stroke 532/2573 (20.7) 263/1089 (22.6) 0.020
Diabetes mellitus 507/2600 (19.5) 209/1092 (19.1) 0.800
Atrial fibrillation 254/2547 (10.0) 93/1064 (8.7) 0.252
SBP, mm Hg 151.2 (22.8) 153.3 (23.7) 0.009
OTT, min 170 (128–210) 190 (142–234) <0.001
DNT, min 30 (14–55) 35 (18–61) <0.001
NIHSS score 6.0 (3.0–10.0) 5.0 (3.0–9.0) 0.010
TOAST classification 0.639
  LAA 1297 (49.4) 538 (47.7)
  CE 304 (11.6) 124 (11.0)
  SAO 814 (31.0) 378 (33.5)
  ODC 63 (2.4) 24 (2.1)
  UND 149 (5.7) 65 (5.8)
Hospital classification 0.417
  Tertiary 2418 (90.7) 1047 (91.5)
  Secondary 248 (9.3) 97 (8.5)
Data are n/N (%), mean (SD) or median (IQR).
BMI, body mass index; CE, cardioembolism; DNT, door- to- needle time; LAA, large- artery atherosclerosis; NIHSS, National Institutes of Health 
Stroke Scale; ODC, stroke of other determined cause; OTT, onset- to- treatment time; r- tPA, recombinant tissue plasminogen activator; SAO, 
small- artery occlusion; SBP, systolic blood pressure; TOAST, Trial of Org 10172 in Acute Stroke Treatment; UK, urokinase; UND, stroke of 
undetermined cause.
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000 000 U) where there were no significant differences in 
baseline characteristics between the two groups (online 
supplemental table S1). The primary endpoint of excel-
lent recovery (mRS scores 0 to 1) was similar between 
the two groups: r- tPA (71.5%) and UK (69.2%), OR 1.12 
(95% CI 0.90 to 1.39, p=0.316). The secondary clinical 
safety outcomes were also comparable between the two 
groups (online supplemental table S2).
We also performed dichotomised analysis by NIHSS 
scores 1–5 and 6–10 in patients with 0.9 mg/kg r- tPA 
versus 1.0–1.5×1 000 000 U UK, where again there was 
similar effectiveness and safety outcomes (online supple-
mental table S3 and S4).
DISCUSSION
This large multicentre prospective registry study specif-
ically designed to compare r- tPA with UK in patients 
with AIS has shown that they are associated with similar 
effectiveness and safety outcome that are relevant to ‘real 
world’ clinical practice in China.
As second- generation thrombolytic drug, r- tPA, a serine 
protease that converts the proenzyme plasminogen into the 
proteinase plasmin, was approved as the standard thrombo-
lytic treatment for AIS across the world on the basis of the 
National Institutes of Stroke and Neurological Diseases trial, 
published in 1995.6 However, the first- generation thrombo-
lytic agent UK, which acts directly to convert plasminogen to 
plasmin,7 has also undergone investigations in AIS,1 8–10 most as 
low dose administered over several days (240 000–600 000 U/
day).8–10 However, a Chinese national muticentre UK trial 
showed that two higher doses of UK (1 000 000 or 1 500 000 
U/patient) given over 30 min were similarly effective when 
administered within 6 hours of AIS,2 which resulted in it 
being approved for use (class II, level B).1 3 However, these 
results were criticised outside of China,11 which together 
with its variable supply have made UK seldom used for AIS 
outside of Asia. Prior to the advent of modern endovascular 
clot retrieval, intra- arterial UK was a popular treatment of 
large vessel occlusive AIS on the basis of several positive small 
trials,12–16 and despite the potential of a higher bleeding risk 
due to its low fibrin specificity.7 Our study is the first indirect 
comparison of r- tPA and UK, where the possibly similar effec-
tiveness and safety to r- tPA, but much lower price, makes UK 
an attractive option in low resource settings. The lower rate 
of sICH and higher rate of excellent recovery found in our 
study is comparable with an early study.4 17 The lower rate of 
sICH in our study compared with ECASS II and ECASS III 
study could possibly be due to the inclusion of patients with 
predominantly mild neurological deficits, ethnic differences 
in risk and where some patients were given lower doses of 
the agents in practice. A meta- analysis has shown that the 
risk of sICH according to SITS- MOST ranged from 1.5% for 
AIS with NIHSS scores of 0–4 and ≥22, respectively,18 while 
a retrospective study showed the risk of sICH was 1.8%.19 
Table 3 Sensitivity analysis for different methods of adjustment
Outcome
Adjusted OR or mean 
difference (95% CI)* P value
Adjusted OR or mean 
difference (95% CI)† P value
mRS scores 0 to 1 at 90 days 1.19 (1.00 to 1.42) 0.047 1.15 (0.98 to 1.35) 0.078
mRS scores 0 to 2 at 90 days 1.27 (1.04 to 1.56) 0.021 1.22 (1.01 to 1.46) 0.036
mRS distribution at 90 days 0.060 0.140
ΔNIHSS score to 24 hours‡ 0.24 (−0.07 to 0.55) 0.125 0.23 (−0.10 to 0.57) 0.173
ΔNIHSS score to 14 days‡ 0.28 (−0.09 to 0.65) 0.133 0.28 (−0.14 to 0.70) 0.194
sICH at 36 hours 0.72 (0.36 to 1.43) 0.349 0.69 (0.35 to 1.35) 0.281
Other bleeding events 1.43 (0.64 to 3.19) 0.384 1.48 (0.66 to 3.29) 0.341
Recurrent stroke at 90 days 0.57 (0.34 to 0.95) 0.030 0.57 (0.34 to 0.94) 0.028
All- cause mortality at 90 days 0.74 (0.49 to 1.11) 0.148 0.76 (0.52 to 1.12) 0.164
*Adjustment with all baseline variables in the model.
†Propensity scores used to adjust all baseline variables in the model.
‡From baseline.
mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; rt- PA, recombinant tissue plasminogen activator; sICH, 
symptomatic intracerebral haemorrhage; UK, urokinase.
Figure 1 Distribution of modified Rankin Scale (mRS) score.
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The multinational Enhanced Control of Hypertension ANd 
Thrombolysis strokE Study (ENCHANTED) clinical trial 
showed that sICH occurred in 1.0% of the participants in low- 
dose compared with in 2.1% standard- dose rtPA groups.20
The strengths of our study include the large sample 
size, minimum selection bias from the consecutive 
recruitment of patients into a prospective registry and the 
systematic data collection of variables within routine prac-
tice. As shown in ENCHANTED,21 there was no clear non- 
inferiority of low (0.6 mg/kg) compared with standard 
(0.9 mg/kg) doses of intravenous r- tPA on functional 
outcomes for thrombolysed patients with AIS with mild–
moderate severity (NIHSS scores 5–6). Our study showed 
that a high dose of UK is associated with comparable clin-
ical outcomes with the use of variable doses of r- tPA, and 
without any increase in sICH: a suitable weight- adjusted 
dose of UK is 250 000×104 U/kg.
However, we recognise several limitations, most impor-
tantly being the lack of randomisation that precluded 
an ability to fully adjust for measured and unmeasured 
confounders. Another is the conduct limited to China, 
where differences in the body mass, comorbid factors 
and patterns of cerebrovascular disease in patients with 
AIS compared with other populations may raise concerns 
over the generalisability of our results. There may also be 
concerns over potential variability in the potency of UK 
across sites in relation to it being sourced from different 
manufacturers. However, all these issues may also 
strengthen the relevance of the findings to current prac-
tice. In addition, we have not collected the premorbid 
mRS in the current study, although all enrolled patients 
were previously well (mRS score 0 or 1). Finally, despite 
the adoption of standardised protocol, the open design 
could have introduced various assessment, reporting and 
indication biases.
CONCLUSIONS
In summary, our prospective national registry study 
suggests that UK may be as safe and effective as r- tPA in 
treating mild to moderate acute ischaemic stroke within 
4.5 hours, on the basis of equivalent outcomes. These 
results provide additional support for guidelines recom-
mending UK as a suitable cost- effective alternative to r- tPA 
for AIS in China. Further multinational, multicentre, 
randomised controlled comparative- effectiveness studies 
of these and other lytic agents may now be warranted.
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